Trials / Completed
CompletedNCT00518427
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: To assess quality of Life (QoL) changes and treatment satisfaction in a real life situation in patients with Type 2 diabetes inadequately controlled on a combination of oral antidiabetic drugs (OAD) plus Neutral Protamine Hagedrone (NHP) insulin treatment that are switched to insulin glargine. Secondary objective: To determine: change in HbA1c, comparision of the incidence of symptomatic hypoglycemia and severe hypoglycemia before and after introduction of insulin glargine, change in weight, change in insulin dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Glargine | Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml. Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment. |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2007-08-20
- Last updated
- 2009-12-07
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00518427. Inclusion in this directory is not an endorsement.